BPC-157 is most frequently prescribed for musculoskeletal injury recovery (tendons, ligaments, joints, fractures), post-surgical rehabilitation, sports recovery, gut health conditions including mucosal inflammation and barrier integrity, and degenerative joint conditions
The SURPASS-CVOT trial demonstrated that tirzepatide reduced the risk of major adverse cardiovascular events by 20% compared to insulin glargine in patients with type 2 diabetes
Meanwhile, new potential peptide drugs are being discovered,24 suggesting promising but as-yet-undetermined directions in the treatment of common health concerns
Both are synthesised by the body and available through diet, with supplementation increasingly used for cardiovascular health, mitochondrial disorders, and male fertility